{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:00:33Z","timestamp":1791583233866,"version":"4.3.4"},"reference-count":40,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Aust N Z J Psychiatry"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Withdrawal from psychoactive medication such as quetiapine is a well-documented phenomenon. Despite the extensive use of quetiapine, there have been few studies into the presence of discontinuation symptoms. We therefore performed a systematic review of published literature for evidence of quetiapine withdrawal or symptoms associated with discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We searched PubMed, Embase, CINAHL, Medline, Web of Science, PsycINFO for articles containing the terms \u2018Quetiapine\u2019 AND \u2018withdraw\n                      <jats:sup>$<\/jats:sup>\n                      \u2019 OR \u2018discontinue\n                      <jats:sup>$<\/jats:sup>\n                      \u2019. We included all study types that reported on somatic withdrawal symptoms and had no language restrictions. We excluded studies where there was withdrawal from multiple medications or any other psychoactive substance, or where the only symptoms were psychological such as rebound psychosis or craving.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We included 13 papers, all of which were individual case reports. The quality of the individual case reports was sub-optimal, as assessed by the CARE Case Report Guidelines. There was an association between rapid cessation of quetiapine and onset of somatic symptoms such as nausea, vomiting, agitation, restlessness, diaphoresis, irritability, anxiety, dysphoria, sleep disturbance, insomnia, tachycardia, hypertension and dizziness. Three studies also reported the onset of a withdrawal dyskinesia characterised by abnormal choreiform movements as well as confusion and speech disturbance in some cases. However, these findings were limited by the number and quality of case reports identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Discontinuation symptoms are an uncommon side effect of quetiapine cessation, which may have clinical implications. Clinicians should therefore be alert to the possibility of quetiapine withdrawal in individuals who present with somatic symptoms or choreiform movements. However, large prospective studies are required to clarify this association.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0004867420965693","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T03:19:03Z","timestamp":1602818343000},"page":"772-783","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Quetiapine withdrawal: A systematic review"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7833-5922","authenticated-orcid":false,"given":"Katherine","family":"Monahan","sequence":"first","affiliation":[{"name":"Metro South Addiction and Mental Health Services, Woolloongabba, QLD, Australia"},{"name":"Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, Australia"},{"name":"West Moreton Health, Ipswich, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimie","family":"Cuzens-Sutton","sequence":"additional","affiliation":[{"name":"School of Nursing, Midwifery and Social Work, The University of Queensland, Woolloongabba, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[{"name":"Metro South Addiction and Mental Health Services, Woolloongabba, QLD, Australia"},{"name":"Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-2924","authenticated-orcid":false,"given":"Steve","family":"Kisely","sequence":"additional","affiliation":[{"name":"Metro South Addiction and Mental Health Services, Woolloongabba, QLD, Australia"},{"name":"Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, Australia"},{"name":"West Moreton Health, Ipswich, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"bibr1-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23089"},{"key":"bibr2-0004867420965693","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130221"},{"key":"bibr3-0004867420965693","unstructured":"AstraZeneca (2018a) Australian product information: Seroqeul (quetiapine fumerate) film coated tablets. Available at: www.guildlink.com.au\/gc\/ws\/astra\/pi.cfm?product=appseroq11019 (accessed 28 September 2020)."},{"key":"bibr4-0004867420965693","unstructured":"AstraZeneca (2018b) Australian product information: Seroquel XR (quetiapine fumerate) modified release tablets. Available at: https:\/\/apps.medicines.org.au\/files\/appserxr.pdf (accessed 28 September 2020)."},{"key":"bibr5-0004867420965693","first-page":"219","volume":"23","author":"Aydin E","year":"2010","journal-title":"Dusunen Adam"},{"key":"bibr6-0004867420965693","first-page":"77","volume":"10","author":"Bogart GT","year":"2011","journal-title":"Current Psychiatry"},{"key":"bibr7-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1080\/14789940903174196"},{"key":"bibr8-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0079-5"},{"key":"bibr9-0004867420965693","doi-asserted-by":"publisher","DOI":"10.3109\/14659891.2013.810309"},{"key":"bibr10-0004867420965693","unstructured":"Datapharm Ltd (2017) Alaquet XL 400 mg prolonged-release tablets, 2017 Edition. Available at: www.medicines.org.uk\/emc\/product\/8712\/smpc#gref"},{"key":"bibr11-0004867420965693","unstructured":"Drug Utilisation Sub-Committee (DUSC) (2013) Drug Utilisation Sub-Committee Review on the utilisation of antipsychotics: Public summary document. Available at: www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2013-08\/antipsychotics (accessed 18 October 2019)."},{"key":"bibr12-0004867420965693","doi-asserted-by":"publisher","DOI":"10.7453\/gahmj.2013.008"},{"key":"bibr13-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1177\/0004867416641195"},{"key":"bibr14-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.135.11.1321"},{"key":"bibr15-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.131617"},{"key":"bibr16-0004867420965693","first-page":"24","volume":"12","author":"Ginsberg DL","year":"2005","journal-title":"Primary Psychiatry"},{"key":"bibr17-0004867420965693","unstructured":"Guzman F (2018) Quetiapine indications: FDA-approved and off-label uses. Available at: https:\/\/psychopharmacologyinstitute.com\/publication\/quetiapine-indications-fda-approved-and-off-label-uses-2112 (accessed 18 October 2019)."},{"key":"bibr18-0004867420965693","first-page":"38","volume":"17","author":"Haridas A","year":"2010","journal-title":"Primary Psychiatry"},{"key":"bibr19-0004867420965693","doi-asserted-by":"publisher","DOI":"10.3109\/00048670903489890"},{"key":"bibr20-0004867420965693","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.33588\/rn.3811.2003635","volume":"38","author":"Jim\u00e9nez-Caballero PE","year":"2004","journal-title":"Revista de Neurologia"},{"key":"bibr21-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.5.1020"},{"key":"bibr22-0004867420965693","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2015036"},{"key":"bibr23-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1080\/15622970701639437"},{"key":"bibr24-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1177\/0004867419851874"},{"key":"bibr25-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006135"},{"key":"bibr26-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20427"},{"key":"bibr27-0004867420965693","volume-title":"MIMS","author":"MIMS","year":"2018"},{"key":"bibr28-0004867420965693","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"bibr29-0004867420965693","unstructured":"PBAC (2018) Public summary document, Pharmacetical Benefits Advisory Committee meeting, March 2018. Available at: www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2018-03\/Quetiapine-psd-march-2018 (accessed 18 October 2019)."},{"key":"bibr30-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.9.1718"},{"key":"bibr31-0004867420965693","doi-asserted-by":"publisher","DOI":"10.12740\/PP\/32923"},{"key":"bibr32-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e3180f62d53"},{"key":"bibr33-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0349.2012.00889.x"},{"key":"bibr34-0004867420965693","first-page":"13","volume":"7","author":"Sansone RA","year":"2010","journal-title":"Psychiatry"},{"key":"bibr35-0004867420965693","first-page":"152","volume":"16","author":"Srivastava A","year":"2013","journal-title":"German Journal of Psychiatry"},{"key":"bibr36-0004867420965693","first-page":"502","volume":"40","author":"Tamburello AC","year":"2012","journal-title":"J Am Acad Psychiatry Law"},{"key":"bibr37-0004867420965693","unstructured":"TGA (2019) Therapeutic goods administration database of adverse event notifications: Medications summary, 11 December 2019 Edition. Available at: www.tga.gov.au\/ (accessed 11 December 2019)."},{"key":"bibr38-0004867420965693","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0810e"},{"key":"bibr39-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.1.173a"},{"key":"bibr40-0004867420965693","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2011.558448"}],"container-title":["Australian &amp; New Zealand Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0004867420965693","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0004867420965693","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0004867420965693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:55:07Z","timestamp":1777373707000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0004867420965693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1177\/0004867420965693"],"URL":"https:\/\/doi.org\/10.1177\/0004867420965693","relation":{},"ISSN":["0004-8674","1440-1614"],"issn-type":[{"value":"0004-8674","type":"print"},{"value":"1440-1614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]}}}